High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Status:
Completed
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if high-dose interleukin-2 (HDIL-2),
when given in combination with recMAGE-A3 + AS15 ASCI (Antigen-Specific Cancer
Immunotherapeutic), can help to control unresectable or metastatic melanoma in patients whose
tumor tissue has the MAGE-A3 protein. The safety of this drug combination will also be
studied. Researchers will also use samples of the original tumor or metastatic tissue (for
example, lymph nodes or liver or lung) that are collected during screening to study if
response to the study drug is related to the genes in the tissue.